NovaTears

Formulated without water, preservatives, phosphates, or surfactants, NovaTears forms a protective barrier over the tear film’s lipid layer, reducing evaporation and supporting the aqueous layer to benefit patients with all forms of dry eye.

It is clinically proven to significantly reduce symptoms within five minutes,¹ improve signs and symptoms within two weeks,^1-3 and sustain improvement over 52 weeks,⁴ with a use-by period of six months after opening.

Contact: AFT Pharmaceuticals (AUS) 1800 238 742 or (NZ) 0800 423 823

References

1. Bacharach J, Kannarr SR, White DE, et al. Early effects of perfluorohexyloctane ophthalmic solution on patient-reported outcomes in dry eye disease: a prospective, open-label, multicenter study. Ophthalmol Ther. 2025;14(4):693-704. doi: 10.1007/s40123-025-01097-z.
2. Tauber J, Berdy GJ, Vittitow JL, et al.; GOBI Study Group. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516-524. doi: 10.1016/j.ophtha.2022.12.021.
3. Sheppard JD, Kurata F, Vittitow JL, et al.; MOJAVE Study Group. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265-274. doi: 10.1016/j.ajo.2023.03.008.
4. Protzko EE, Segal BA, Vittitow JL, et al. Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI study. Cornea. 2024;43(9):1100–1107. doi: 10.1097/ICO.0000000000003418.